Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408587 · ClinicalTrials.gov registry record · Phase 1
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
A Phase 1 study, sponsored by Viralytics.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03408587 is a Phase 1 study that has completed, run by Viralytics. The registered enrollment target is 11 participants.
The verdict
NCT03408587, a Phase 1 study, has completed, sponsored by Viralytics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.
Interventions
- BIOLOGICAL Ipilimumab
- BIOLOGICAL CVA21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03408587
The ClinicalTrials.gov registry entry for NCT03408587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viralytics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT03408587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03408587 about?
NCT03408587 is a clinical study titled "CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)". This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.
What is the current status of trial NCT03408587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2018-01-29. Estimated completion is 2019-05-22.
What interventions are being tested in trial NCT03408587?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), CVA21 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03408587?
This trial is sponsored by Viralytics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.